CN113061163A - Peptide ligand targeting beta-amyloid 1-42 and application thereof - Google Patents

Peptide ligand targeting beta-amyloid 1-42 and application thereof Download PDF

Info

Publication number
CN113061163A
CN113061163A CN202110362980.XA CN202110362980A CN113061163A CN 113061163 A CN113061163 A CN 113061163A CN 202110362980 A CN202110362980 A CN 202110362980A CN 113061163 A CN113061163 A CN 113061163A
Authority
CN
China
Prior art keywords
peptide ligand
beta
amyloid
protein
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110362980.XA
Other languages
Chinese (zh)
Other versions
CN113061163B (en
Inventor
李宁
王方雨
黄现青
宋莲军
张蓓
程永霞
沈玥
乔明武
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henan Agricultural University
Original Assignee
Henan Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan Agricultural University filed Critical Henan Agricultural University
Priority to CN202110362980.XA priority Critical patent/CN113061163B/en
Publication of CN113061163A publication Critical patent/CN113061163A/en
Application granted granted Critical
Publication of CN113061163B publication Critical patent/CN113061163B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to a peptide ligand of a target beta-amyloid 1-42 and application thereof, which searches a peptide ligand P21 with the best combination mode and affinity with a target protein in a virtual peptide ligand database by a molecule docking virtual screening technology on the basis of a beta-amyloid crystal structure by means of computer-aided design, wherein the sequence of the peptide ligand is YVRHLK. Solid phase Synthesis of YVRHLK Using A β1‑42The results of experiments of thioflavin T ThT fluorescence, surface plasmon resonance and cytotoxicity on protein samples respectively show that the peptide ligand P21 is used for treating A beta1‑42The protein aggregation has good binding capacity and consists ofThis demonstrates that peptide ligands designed by the present invention can be used to inhibit A.beta.1‑42Toxicity of the aggregates.

Description

Peptide ligand targeting beta-amyloid 1-42 and application thereof
Technical Field
The invention relates to a peptide ligand of a targeting beta-amyloid 1-42 and application thereof, belonging to the field of peptide ligand design and drug screening development.
Background
With the continuous development of science and technology in recent years, computer application is becoming more important in the field of biology, and the molecular docking virtual screening technology based on computer simulation is a research hotspot for rational design and screening of affinity peptides in recent years. The method is characterized in that continuous butt joint of peptide aglucon small molecules on active sites of target protein molecules is realized by means of computer fast operation, the peptide aglucons are mostly from a prepared virtual peptide library, then the peptide aglucons capable of being combined with the target protein are found through virtual butt joint with the target protein, the combination mode of the peptide aglucons and the target protein is calculated through computer software and scored, ligands which are well combined with the target protein are selected according to the scoring result, and in-vitro experiment screening and verification are used after synthesis.
The number of patients suffering from Alzheimer Disease (AD) in China exceeds 900 million, patients suffering from early mild cognitive impairment exceed 2300 million, the number of patients suffering from AD exceeds 2000 million by 2050, the people are countries with the largest AD population and the highest growth speed in the world, and heavy burden is brought to the patients, families, society and medical treatment. In the elderly population over 60 years of age, the risk of AD increases by approximately 1.85-fold for every 5 years of age. Therefore, the economic burden and social problems caused by AD are becoming more serious and have become one of the great challenges facing the whole human being. The excessive aggregation of amyloid beta-protein (A β) and hyperphosphorylation of Tau protein are two major hypotheses that we consider the development of AD. Many scholars believe that APP appears after cleavageSenile plaques formed by deposition of a β are a major cause of the onset of AD, and thus, prevention of a β aggregation is a promising approach for the treatment of AD. The existing research proves that the soluble Abeta oligomer has the greatest toxicity, and mainly activates the approaches of neuroglia cell triggering inflammatory reaction and the like by influencing cell membrane ion channels, generating oxidative stress, and activating the neuroglia cell. A beta exists in various forms in human body, mainly in A beta1-42And Abeta1-40Mainly, wherein A beta1-42This has been the focus of research because it is more toxic and more prone to aggregation.
Disclosure of Invention
The invention searches a peptide ligand P21 with the best combination mode and affinity with a target protein in a virtual peptide ligand database by a molecular docking virtual screening technology on the basis of a beta amyloid protein crystal structure by means of computer-aided design, and the sequence of the peptide ligand P21 is YVRHLK. Solid phase Synthesis of YVRHLK Using A β1-42The results of experiments of thioflavin T (ThT) ThT fluorescence, Surface Plasmon Resonance (SPR) and cytotoxicity on protein samples respectively show that the peptide ligand P21 is used for A beta1-42Protein aggregation has good binding capacity, thus proving that the peptide ligand designed by the invention can be used for inhibiting A beta1-42Toxicity of the aggregates.
In order to achieve the purpose, the invention adopts the technical scheme that:
a peptide ligand P21 targeting beta-amyloid 1-42, wherein the sequence of the peptide ligand P21 is YVRHLK.
The peptide ligand P21 comprises a corresponding modification of the peptide ligand P21 with the peptide ligand P21 as a core; the modified material comprises nano material, fluorescent material, enzyme and biotin.
The peptide ligand P21 is used for inhibiting the toxicity of beta-amyloid 1-42.
The peptide ligand P21 is applied to the detection of beta-amyloid 1-42.
The peptide ligand P21 is applied to the preparation of the beta-amyloid 1-42 targeted drug.
The invention has the beneficial effects that:
1. the invention obtains a peptide ligand sequence P21 specifically combined with beta-amyloid by a molecular docking virtual screening technology based on a beta-amyloid crystal structure (PDB ID:6SHS), wherein the peptide ligand sequence is YVRHLK. Solid phase synthesis of peptide ligand, affinity identification of beta-amyloid protein, P21 sequence and A beta1-42Equilibrium dissociation constant K of interactions between proteinsDIs 5.385X 10-5M, indicates that the affinity is better.
2. The P21 peptide ligand sequence of the invention has no toxicity to PC12 cells to a certain extent and has no toxicity to A beta1-42The PC12 cell damage caused by the protein has better protection effect, and has the advantages of convenience, high efficiency and low cost.
Drawings
FIG. 1 shows the sequence of P21 and A.beta.1-42And (4) displaying the docking result of the protein.
FIG. 2 shows that the P21 sequence inhibits A.beta.1-42Graph of the effect of protein aggregation.
Wherein A.beta.represents a compound containing only A.beta.1-42A sample; p21+ Abeta indicates P21 and Abeta1-42The mixed sample of (1).
FIG. 3 shows the sequence of P21 and A.beta.1-42And (3) identifying the LSPR affinity of the protein.
Wherein the ordinate represents the signal value detected by the sensor; the abscissa represents the time of interaction of the sample in the sensor.
FIG. 4 shows the effect of the P21 sequence on the viability of PC12 cells.
Wherein the abscissa represents the peptide ligand concentration and the ordinate represents the cell viability.
FIG. 5 shows the P21 sequence and A.beta.at different concentrations1-42Protein co-incubation followed by A β -pairing1-42Effects of protein toxicity.
Detailed Description
The following examples further illustrate the embodiments of the present invention in detail.
Example 1 molecular docking and screening of virtual peptide libraries
1、Aβ1-42Preparation of protein Crystal Structure
For Abeta by means of computer aided design software1-42The crystal structure of the protein (PDB ID:6SHS) was analyzed, and the 16 th to 23 th amino acid residues were selected as the designated docking region for molecular docking.
2. Design of virtual peptide ligand libraries
The invention adopts a mode of prolonging amino acid residues one by one, firstly, several amino acid libraries with the highest scores are butted with the structure of a target protein one by one, the optimal amino acid residue is selected as a core according to the butting condition, and then the corresponding amino acid number is sequentially increased until the optimal butting result is reached. The peptide sequences generated from the library of virtual peptide ligands preferably have amino acid residues from 3 to 12.
3. Assessment of docking results
Respectively calculating the binding free energy of peptide ligand and protein, hydrogen chain and Van der Waals force, etc. to make comprehensive evaluation, and using Cscore value to judge screening result to obtain P21, its peptide ligand sequence is YVRHLK, and its peptide ligand sequence is connected with Abeta1-42The results of the protein docking interactions are shown in FIG. 1.
Example 2P 21 sequence and A.beta.1-42Fluorescent intensity identification of protein binding
1. First is Abeta1-42Preparation of monomers from Abeta1-42Dissolving in Hexafluoroisopropanol (HFIP) at 1mg/mL, standing for 1 hr, ultrasonic treating for 10 min after dissolving sufficiently, volatilizing HFIP completely in a fume hood, storing in a refrigerator at-80 deg.C, and dissolving in PBS buffer (containing 100mM PB and 10mM NaCl, pH7.4) when in use.
2. The obtained P21 sequence was dissolved in PBS buffer (containing 100mM PB, 10mM NaCl, pH 7.4). During the experiment, Abeta is added1-42Mixing the monomer solution and the P21 solution, and mixing A beta1-42The final concentration was 25. mu.M, and the final concentration of P21 was 50. mu.M.
3. The mixed samples were incubated together in an incubator at 37 ℃ for 24 hours, and 20. mu.L of the sample was taken. ThT fluorescence intensity was measured at an excitation wavelength of 440nm and an emission wavelength of 480nm after 20-fold dilution with ThT staining solution (containing 25. mu.M ThT, 25mM PB). Will contain only A beta1-42The fluorescence intensity of the sample was set to 100%, and normalization treatment was performed (See fig. 2).
The results show that the P21 sequence is specific to the synthesized A beta1-42The in vitro aggregation of the protein has good inhibition effect.
Example 3P 21 sequence and A β1-42Affinity identification of proteins
1. The appropriate pH was determined as the coupling conditions. In the reaction of Abeta1-42Before the protein is fixed on the CM5 chip, a proper buffer solution pH needs to be screened, so that the ligand is enriched to the vicinity of the surface of the CM5 chip through electrostatic adsorption, and a better coupling effect is achieved. Diluting A beta with sodium acetate solution of pH5.5, 5.0, 4.5, 4.01-42The sample was 50. mu.g/mL. The loading time was 180s, 50mM NaOH was used as a washing solution, and pH4.5 was used as a coupling condition according to the results.
2. And (3) ligand coupling. Immobilization of Abeta Using amino direct coupling1-42Proteins were applied to the surface of CM5 chips. Flow Cell 1 was selected as the reference channel and Flow Cell 2 as the sample channel. The coupling mode was chosen as specific contact time. Then according to the sample position diagram, HBS-EP buffer solution, EDC/NHS solution and A beta dissolved in sodium acetate with pH4.5 are correspondingly put in one to one1-42Adding the solution and ethanolamine solution into a sample tray, checking a buffer solution, and storing a method and a result file; click Run, begin formal coupling.
3. And (4) measuring the affinity. Run Kinetics/Affinity assay click Kinetics/Affinity was chosen to set the relevant experimental parameters, Flow Cell 1 and 2 and chip type CM5 were chosen. Startup's solution is HBS-EP buffer, binding time 120s, dissociation time 120s, regeneration solution is 0.25% Sodium Dodecyl Sulfate (SDS), and stabilization time 30 s. Fill out sample name P21, dissolve the sample in HBS-EP buffer, dilute to peptide ligand solution with concentration of 50. mu.M, 25. mu.M, 12.5. mu.M, 6.25. mu.M, 3.12. mu.M, 1.56. mu.M, 0.78. mu.M, and set a zero concentration and a minimum concentration repeat sample, place the sample as required, check the buffer, save the file, click Run to start the experiment. Ligand coupling and affinity determination were both accomplished using Biacore X100 Control Software.
4. And (6) data processing. After the experiment, the results were analyzed by Evaluation software, and the background signal of Flow Cell 1 was subtracted from Flow Cell 2 to obtain the experimental results. The fitting was performed using a 1:1binding fitting method (see fig. 3). The concentration of the solution decreases gradually from the top to the bottom of the graph.
The results show that as the concentration of P21 is increased, the binding amount is larger, the response time is fast, and the P21 sequence is applied to the synthesized A beta1-42The protein has better affinity combination, and the equilibrium dissociation constant K of the interaction between the protein and the proteinDIs 5.385X 10- 5M。
Example 4 toxicity characterization of P21 peptide ligands
1. Peptide ligand sample preparation. The P21 peptide ligand was dissolved in DMEM complete medium (DMEM high-glucose medium containing 10% fetal bovine serum, containing 4.5g/L glucose, L-glutamine, and sodium pyruvate) to prepare peptide ligand solutions of various concentrations (3.125, 6.25, 12.5, 25, 50, 100, and 200. mu.M) for further experiments.
2. And (5) plating cells. Selecting PC12 cells in logarithmic phase of growth, washing twice with PBS, adding 1-2mL trypsin, digesting at 37 deg.C for 1min, tapping the side of the culture flask, observing the cell state under an inverted microscope, adding DMEM complete culture medium to stop digestion when the cell gap becomes large and round, gently blowing the cells down, transferring to a centrifuge tube, centrifuging at 1000r/min for 5 min, discarding the supernatant, adding new DMEM complete culture medium, counting by a cell counting plate, and diluting to 5 × 10 density4Cell suspension at 100. mu.L/well (5X 10)3One/hole) planking.
3. The CCK-8 method is used for detecting the cell viability. After the cells are attached to the wall, peptide ligand solutions with different concentrations are added, each concentration is 5 multiple wells, the administration group is used as the administration group, the control group is added with only the culture medium solution, and the blank group is used as the well added with 100 mu L of the culture medium and 10 mu L of CCK-8 solution but not added with the cells. After incubation at 37 ℃ for 24h, 10. mu.L of CCK-8 solution was added to each well, incubation was continued in a cell incubator for 2 hours, and absorbance was measured at 450 nm. Cell viability ═ 100% (dose-blank)/(control-blank) (see figure 4).
The results show that the toxicity of the P21 is increased with the increase of the concentration of the P21, but the P21 sequence has no statistical difference and is not toxic to PC12 cells to a certain extent.
Example 5P 21 peptide ligands inhibit A.beta.1-42Identification of toxicity
1. And (4) sample preparation. beta-Abeta prepared at the previous stage1-42The monomer and the P21 peptide ligand are respectively dissolved in DMEM complete medium to obtain the final concentration of Abeta1-42mu.M, 50. mu.M sample of P21 peptide ligand was incubated at 37 ℃ for 72 h.
2. And (5) plating cells. Selecting PC12 cells in logarithmic phase of growth, washing twice with PBS, adding 1-2mL trypsin, digesting at 37 deg.C for 1min, tapping the side of the culture flask, observing the cell state under an inverted microscope, adding DMEM complete culture medium to stop digestion when the cell gap becomes large and round, gently blowing the cells down and transferring to a centrifuge tube, centrifuging at 1000r/min for 5 min, discarding the supernatant, adding new DMEM complete culture medium, counting by a cell counting plate, diluting to 5 × 10 density4Cell suspension at 100. mu.L/well (5X 10)3One/hole) planking.
3. The CCK-8 method is used for detecting the cell viability. Respectively adding Abeta after the cells adhere to the wall1-42Monomer sample, and A beta in the presence of P21 peptide ligand inhibitor1-42Monomer sample (A beta)1-42Mixed volumes of monomer and P21 peptide ligand such as in fig. 5), 5 multiple wells per concentration, for administration groups; a control group was prepared by adding only the medium solution, wells to which 100. mu.L of the medium and 10. mu.L of the CCK-8 solution were added but no cells were added were used as a blank group, and after culturing at 37 ℃ for 24 hours, 10. mu.L of the CCK-8 solution was added to each well, and the culture was continued in a cell incubator for 2 hours, and the absorbance at 450nm was measured. Cell viability ═ 100% (dose-blank)/(control-blank) (see figure 5).
The results show that the A beta 1-42 has a large influence on the cell viability of the PC12, and the cell viability is increased after the P21 and the A beta 1-42 are incubated together, and the cell viability is increased when the A beta: the highest is reached when the peptide ligand is 1:4, P21 sequence pair A beta1-42The damage of the PC12 cells caused by the method has better protective effect.
Sequence listing
<110> Henan university of agriculture
<120> a peptide ligand targeting beta-amyloid 1-42 and application thereof
<130> amyloid beta 1-42
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 6
<212> PRT
<213> Artificial sequence ()
<400> 1
Tyr Val Arg His Leu Lys
1 5

Claims (5)

1. A peptide ligand P21 targeting beta-amyloid 1-42, wherein the sequence of the peptide ligand P21 is YVRHLK.
2. The peptide ligand P21, according to claim 1, wherein the peptide ligand P21 is the core and the peptide ligand P21 is modified accordingly; the modified material comprises nano material, fluorescent material, enzyme and biotin.
3. Use of the peptide ligand P21 of claim 1 or 2 for inhibiting the toxicity of β -amyloid 1-42.
4. Use of the peptide ligand P21 of claim 1 or 2 for detecting β -amyloid 1-42.
5. Use of the peptide ligand P21 of claim 1 or 2 for the preparation of a medicament for targeting β -amyloid 1-42.
CN202110362980.XA 2021-04-02 2021-04-02 Peptide ligand targeting beta-amyloid 1-42 and application thereof Active CN113061163B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110362980.XA CN113061163B (en) 2021-04-02 2021-04-02 Peptide ligand targeting beta-amyloid 1-42 and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110362980.XA CN113061163B (en) 2021-04-02 2021-04-02 Peptide ligand targeting beta-amyloid 1-42 and application thereof

Publications (2)

Publication Number Publication Date
CN113061163A true CN113061163A (en) 2021-07-02
CN113061163B CN113061163B (en) 2023-06-02

Family

ID=76565673

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110362980.XA Active CN113061163B (en) 2021-04-02 2021-04-02 Peptide ligand targeting beta-amyloid 1-42 and application thereof

Country Status (1)

Country Link
CN (1) CN113061163B (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075507A1 (en) * 2004-02-09 2005-08-18 Affibody Ab Amyloid beta peptide binding polypeptide
CN101199314A (en) * 2006-12-12 2008-06-18 河南农业大学 Novel process for preparing esculent film using glutamine transaminage modified protein
CN104231053A (en) * 2013-06-08 2014-12-24 国家纳米科学中心 Polypeptide for regulating physiological toxicity of beta amyloid protein
CN104277105A (en) * 2013-07-12 2015-01-14 国家纳米科学中心 Polypeptide inhibitor for inhibiting aggregation and toxicity of beta amyloid protein and application of polypeptide inhibitor
CN109942714A (en) * 2019-04-02 2019-06-28 中国药科大学 A kind of functional polypeptide and application
CN110904270A (en) * 2019-11-27 2020-03-24 河南农业大学 Multiplex RT-PCR detection method for porcine delta coronavirus, porcine epidemic diarrhea virus and porcine sapelovirus and application
US20200299328A1 (en) * 2018-05-24 2020-09-24 South China University Of Technology Polypeptide with function of inhibiting abeta 42 protein aggregation and use thereof, and gene encoding the polypeptide
CN111707719A (en) * 2020-06-23 2020-09-25 河南农业大学 Poly-L-cysteine and reduced graphene oxide loaded nano-silver modified glassy carbon electrode and application thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075507A1 (en) * 2004-02-09 2005-08-18 Affibody Ab Amyloid beta peptide binding polypeptide
CN101199314A (en) * 2006-12-12 2008-06-18 河南农业大学 Novel process for preparing esculent film using glutamine transaminage modified protein
CN104231053A (en) * 2013-06-08 2014-12-24 国家纳米科学中心 Polypeptide for regulating physiological toxicity of beta amyloid protein
CN104277105A (en) * 2013-07-12 2015-01-14 国家纳米科学中心 Polypeptide inhibitor for inhibiting aggregation and toxicity of beta amyloid protein and application of polypeptide inhibitor
US20200299328A1 (en) * 2018-05-24 2020-09-24 South China University Of Technology Polypeptide with function of inhibiting abeta 42 protein aggregation and use thereof, and gene encoding the polypeptide
CN109942714A (en) * 2019-04-02 2019-06-28 中国药科大学 A kind of functional polypeptide and application
CN110904270A (en) * 2019-11-27 2020-03-24 河南农业大学 Multiplex RT-PCR detection method for porcine delta coronavirus, porcine epidemic diarrhea virus and porcine sapelovirus and application
CN111707719A (en) * 2020-06-23 2020-09-25 河南农业大学 Poly-L-cysteine and reduced graphene oxide loaded nano-silver modified glassy carbon electrode and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI XING ET AL: "Maternal Lead Exposure Induces Down-regulation of Hippocampal Insulin-degrading Enzyme and Nerve Growth Factor Expression in Mouse Pups", 《BIOMED ENVIRON SCI》, vol. 30, no. 3, pages 215 - 219, XP029996031, DOI: 10.3967/bes2017.029 *

Also Published As

Publication number Publication date
CN113061163B (en) 2023-06-02

Similar Documents

Publication Publication Date Title
EP2238241B1 (en) Selective differentiation, identification, and modulation of human th17 cells
Kliewe et al. Fibronectin is up‐regulated in podocytes by mechanical stress
Burgstahler et al. NO modulates the apicolateral cytoskeleton of isolated hepatocytes by a PKC-dependent, cGMP-independent mechanism
WO2021097980A1 (en) Caspase-3 inhibitor and use thereof
WO2011126882A2 (en) Therapeutic peptides and their derivatives and therapeutic uses thereof
WO2000046404A1 (en) Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
JP2015508155A (en) Soluble MANF in pancreatic beta cell injury
Li et al. Design of a Gag pentapeptide analogue that binds human cyclophilin A more efficiently than the entire capsid protein: new insights for the development of novel anti-HIV-1 drugs
Lira et al. Anionic Ultrasmall gold nanoparticles bind to coagulation factors and disturb Normal hemostatic balance
Li et al. Nanoparticles induced by embedding self‐assembling cassette into glucagon‐like peptide 1 for improving in vivo stability
US20140256614A1 (en) Compositions and methods for augmenting permeability barriers
CN113061163A (en) Peptide ligand targeting beta-amyloid 1-42 and application thereof
CN113061162A (en) Polypeptide targeted and combined with beta-amyloid 1-42 and application thereof
US20100022504A1 (en) Methods for treating latent tuberculosis
CN113061160A (en) Targeted Abeta inhibitory polypeptide and application thereof
CN113072618A (en) Peptide ligand of targeting analog-beta structure and application
CN113061161A (en) Inhibitory peptide ligand targeting amyloid-beta structure and application thereof
WO2005071116A1 (en) Modulation of hsv infection
CN113045626A (en) Polypeptide for inhibiting amyloid-beta focusing and application thereof
CN112409450A (en) Affinity agent of TIGIT-IgV and application thereof
Youcef et al. Tissue kallikrein is required for the cardioprotective effect of cyclosporin A in myocardial ischemia in the mouse
US20120295292A1 (en) Detecting Protein Arginine Deiminase (PAD) Activity in Human Tissues and Sera
JP4904269B2 (en) Methods for screening carnitine transporter agonists or antagonists and uses thereof
US20100316622A1 (en) Diagnosis and treatment of cardiac disorders
Bellotti et al. Protein misfolding diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant